November 2024 in “Journal of Investigative Dermatology” Understanding snoRNA regulation may help slow skin aging.
December 2024 in “European journal of medical research”
Bio-nanovesicles could improve hair and skin regeneration by delivering important molecules to repair and heal.
44 citations
,
May 2023 in “MedComm” PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.
January 2025 in “Nanoscale” Boron/nitrogen-doped carbon nano-onions improve targeted breast cancer treatment by enhancing drug delivery and reducing side effects.
March 2026 in “Pharmaceutics” Plant-derived nanovesicles show promise in cancer treatment but need standardized preparation.
85 citations
,
July 2025 in “Nature Communications” Nanozymes greatly improve biocatalysis by being stable, efficient, and versatile.
March 2026 in “Journal of Nanotheranostics” Nanotechnology improves CRISPR-Cas9 delivery for cancer treatment, but challenges remain.
January 2016 in “Munich Personal RePEc Archive (Ludwig Maximilian University of Munich)” A new method using gold nanoshells and infrared light effectively delivers siRNA to cancer and stem cells with precision and minimal damage.
6 citations
,
January 2020 in “The journal of investigative dermatology/Journal of investigative dermatology” New topical treatment using spherical nucleic acids shows promise in reducing psoriasis inflammation.
42 citations
,
November 2022 in “Cosmetics” Niosomes improve the effectiveness of skin and hair cosmetics.
112 citations
,
November 2023 in “Nano-Micro Letters” Nanozymes show promise for effective and safe cancer treatment.
January 2025 in “The Pharma Innovation” Nanospanlastic vesicles can improve glaucoma treatment by enhancing drug delivery to the eye.
72 citations
,
December 2012 in “Expert Opinion on Drug Delivery” Niosomes are promising for skin drug delivery, offering benefits like improved drug penetration and stability.
April 2026 in “Future Medicinal Chemistry” PROTACs have become a breakthrough in medicine by effectively targeting and degrading specific proteins to treat diseases.
15 citations
,
October 2012 in “InTech eBooks” Niosomes are a promising and effective way to deliver drugs through the skin.
2 citations
,
November 2024 in “In Silico Pharmacology” 3 citations
,
October 2025 in “Cancer” PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.
March 2022 in “Clinical Cosmetic and Investigational Dermatology” CDKN2AIP gene is less active in nevus sebaceous, affecting related RNA networks.
April 2018 in “Journal of Investigative Dermatology” The research found that blocking a gene called NEMO can potentially prevent harmful effects of aging at the cellular level.
1 citations
,
January 2024 in “Journal of molecular structure” The new finasteride delivery system using chitosan-based nanoniosomes shows promise for prostate cancer prevention.
March 2025 in “Nature Communications” NSC167409 can effectively inhibit the virus causing hand, foot, and mouth disease.
34 citations
,
October 2021 in “Scientific Reports” Nobiletin-loaded vesicles effectively treat skin cancer by restoring normal miRNA and antioxidant levels.
6 citations
,
September 2014 in “Journal of the American Academy of Dermatology” Researchers found a potential new type of skin growth called follicular mucinous nevus.
January 2026 in “ACS Applied Bio Materials” A new treatment using nanoliposomes can improve hair regrowth in androgenetic alopecia.
10 citations
,
October 2018 in “Journal of molecular and cellular cardiology/Journal of Molecular and Cellular Cardiology” The gene NM_026333 slows down aging by affecting the NCX1 pathway and could be targeted for anti-aging treatments.
37 citations
,
December 2020 in “Molecules” A new delivery system makes Curcumin more effective and safer against viruses.
14 citations
,
August 2014 in “The FASEB Journal” CAP1/Prss8 does not activate PAR2 or inhibit PN-1.
September 2023 in “HAL (Le Centre pour la Communication Scientifique Directe)” Peptide nanoparticles can effectively deliver CRISPR-Cas9 to target KRAS mutations in cancer.